Poseida Therapeutics Appoints Luke Corning to Board of Directors
SAN DIEGO, Dec. 17, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Luke Corning, Portfolio Manager and Head of Credit at Pentwater Capital Management, to its Board of Directors.
"We are pleased to welcome Mr. Corning to Poseida's Board of Directors," said Eric Ostertag, M.D., Ph.D., and Chief Executive Officer of Poseida Therapeutics. "Luke and Pentwater have been strong supporters of Poseida and our mission since first investing in our Series C preferred stock financing and subsequently investing in our Series D financing and IPO. His investment acumen and expertise in corporate finance complement the capabilities of our Board, as we continue to focus on advancing Poseida's extensive pipeline of cell and gene therapies currently in development."
Mr. Corning currently manages the credit team at Pentwater Capital Management, where he has held several key positions since 2014. Prior to this role, he spent eight years as the senior investment professional at a private Chicago based proprietary trading and investment firm. Mr. Corning began his career as an analyst at Goldman, Sachs & Co. in 2004. He holds a B.S. in finance from Miami University of Ohio, and is an alumnus of the Program for Leadership Development at Harvard Business School. Luke serves on a number of boards of directors, including Malin Corporation, Plc, one of Poseida's early investors.
"It is an honor to join the pioneers in gene therapy at Poseida Therapeutics as the Company continues to make significant progress across its clinical and developmental pipeline," said Mr. Corning. "I look forward to supporting Poseida as it continues to advance important new therapeutic candidates for patients in need."
The company also announced that Sean Murphy, an Executive Vice President of Malin Plc and a member of Poseida's Board of Directors since 2018 will not stand for re-election at the Company's 2021 annual meeting of stockholders.
About Poseida Therapeutics, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/poseida-therapeutics-appoints-luke-corning-to-board-of-directors-301194648.html
SOURCE Poseida Therapeutics, Inc.
Company Codes: NASDAQ-NMS:PSTX